Risk Factors Associated With Hyaluronic Acid Filler-Related Delayed Complications: A Literature Review and Expert Consensus

September 2026 | Volume 25 | Issue 9 | 785 | Copyright © September 2026


Published online August 29, 2026

Joel L. Cohen MDa, Julie Woodward MDb, Sheila Barbarino MD FACSc, Steven Weiner MDd, Young Cho MDe, Kim Nichols MDf, Charles Boyd MDg, Jessica Hicks PhDh*, Kandy Bouquet RNh, Jaymie Gordon PharmDh, David K. Funt MDi

aAboutSkin Dermatology and Aesthetics, Denver, CO
bDuke Aesthetic Center, Durham, NC
cBarbarino Surgical Arts, Redondo Beach, CA and Austin, TX
dAesthetic Clinique, Santa Rosa Beach, FL
eIntegrated Aesthetics, Spring, TX
fNicholsMD, Greenwich, CT
gBoyd Beauty, Birmingham, MI
hGalderma Laboratories, L.P., Dallas, TX
iFunt Aesthetics, Long Island, NY

Abstract
Background: Delayed complications associated with hyaluronic acid (HA) fillers are a concern in aesthetic medicine. However, clinical strategies for mitigation remain inconsistent, and guidelines often make recommendations that may lack the support of robust evidence. To address this gap, a multidisciplinary expert safety council convened to develop evidence-based recommendations aimed at reducing the delayed complication risk of soft-tissue augmentation with fillers, noting which recommendations are uncertain due to lack of evidence.
Methods: A structured advisory board meeting was held with 8 United States-based experts in aesthetic injectables. Discussions were informed by a comprehensive literature review, pre-meeting surveys, and real-time polling, with consensus statements refined following the meeting.
Results: The council reached full consensus on 8 key recommendations across 4 risk factor categories: patient history, product characteristics, procedural technique, and postprocedure care. A consistent theme across all categories was the lack of robust clinical evidence supporting many current guidelines, underscoring the need for more evidence-based recommendations.
Conclusion: This expert consensus highlights the need for evidence-informed approaches to HA filler safety. While definitive data remain limited, the panel offers a practical framework for minimizing delayed complications and identifying priorities for future research.

 

INTRODUCTION

Hyaluronic acid (HA) filler injection is the second most commonly performed nonsurgical aesthetic procedure globally. HA filler use has risen sharply, driven by advantages over earlier collagen-based fillers, such as limited immunogenicity, reduced migration after injection, longer duration of effect, and ease of use.1 While HA fillers have a well-established long-term safety profile, recent United States Food and Drug Administration (FDA) updates have strengthened warnings about delayed-onset inflammation near injection sites, prompting increased concern from patients and clinicians.2-4

Complications arising from HA filler procedures are generally categorized as early or late reactions.2 Early reactions occur within 14 days of the procedure and may include bruising, hives, itching, swelling, or allergy, including anaphylaxis.2,5 Early complications are typically minor and caused by the injection technique or the normal inflammatory response.1 Delayed complications are broadly defined as those occurring ≥14 days postprocedure.2 Importantly, definitions across guidelines vary for what is considered "early" or "late,"1 and others categorize reactions based on type (ie, allergic or hypersensitivity reactions [early] vs immune-mediated reactions [delayed]).5-7 The true incidence of delayed-onset reactions is difficult to determine,